Suraj Gathani, MD
Family Medicine · Louisville, KYNPI 1902172067
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,455 of the $69,406 with a category attached, or 61.2%. 57 manufacturers reported payments, led by Phathom Pharmaceuticals, Inc. at 31.1% of the total. Reporting peaked in 2024 at $21,095 and has fallen 62.1% since, to $7,991 in 2025. Among family medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,576 payments — averaging $44.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$22K
- Biohaven Pharmaceutical Holding Company Ltd.$12K
- Biohaven Pharmaceuticals, Inc.$10K
- AbbVie$7K
- Bausch Health US, LLC$2K
- Novo Nordisk$2K
- plus $14K from 51 others
What the payments were for
- Speaking & faculty fees$42,45561%
- Travel & lodging$3,1665%
- Food & beverage$23,74334%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$21,321
- VOQUEZNA$20,215
- UBRELVY$4,841
- FARXIGA$891
- AIRSUPRA$772
- Kerecis Omega3 Marigen$657
- Kerecis Omega3 SurgiClose$489
- BREZTRI$376
- LOKELMA$276
- FASENRA$173
- Repatha$126
- AIMOVIG$125
- EVENITY$120
- Kerecis Omega3 GraftGuide$118
- Ozempic$118
- Kerendia$118
- QULIPTA$116
- TRINTELLIX$114
- MOUNJARO$113
- Wegovy$112
How this compares
$69,406 in reported general payments places this provider in the 95th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 144 | $147,635 |
| OzempicSemaglutide | 139 | $133,326 |
| FarxigaDapagliflozin Propanediol | 103 | $80,414 |
| EliquisApixaban | 61 | $70,838 |
| RybelsusSemaglutide | 41 | $50,849 |
| TrulicityDulaglutide | 27 | $42,894 |
| MounjaroTirzepatide | 24 | $36,893 |
| VascepaIcosapent Ethyl | 40 | $29,493 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 24 | $29,145 |
| JanuviaSitagliptin Phosphate | 19 | $22,979 |
| TrintellixVortioxetine Hydrobromide | 25 | $22,561 |
| Repatha SureclickEvolocumab | 41 | $22,347 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $19,594 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 26 | $18,161 |
| XareltoRivaroxaban | 13 | $15,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr | $961 | $191,750184 claims |
| Novo NordiskOzempic, Rybelsus | $1,738 | $184,175180 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,438 | $90,884120 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,120 | $79,78651 claims |
| PfizerEliquis | $1,160 | $70,83861 claims |
| MerckJanuvia, Janumet Xr | $295 | $41,13945 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $918 | $22,56125 claims |
| Johnson & JohnsonXarelto | $331 | $15,09313 claims |
| Astellas Pharma US IncMyrbetriq | $120 | $11,76725 claims |
| BayerKerendia | $680 | $10,83113 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $42 | $10,27231 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $21,584 | $8,77312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Louisville
- Christopher RhyneLouisville$933K
- Mandy WhittLouisville$38K
- Michael PendletonLouisville$29K
- Rajanbhai AminLouisville$26K
- James WrightLouisville$18K
- Rosenberg ReyesLouisville$18K
- Dennis GrayLouisville$14K
- Vincent LangLouisville$12K
- Jaivanti LohanoLouisville$11K
- John RichardLexington$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.